Comparison between Eris Lifesciences IPO and IRB InvIT Fund InvIT.
Eris Lifesciences IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while IRB InvIT Fund InvIT is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Eris Lifesciences IPO is up to ₹1,740.49 Cr whereas the issue size of the IRB InvIT Fund InvIT is up to ₹5,032.88 Cr. The final issue price of Eris Lifesciences IPO is ₹603.00 per share and of IRB InvIT Fund InvIT is ₹102.00 per share.
| Eris Lifesciences IPO | IRB InvIT Fund InvIT | |
|---|---|---|
| Face Value | ₹1 per share | ₹102 per share |
| Issue Price (Lower) | ₹600.00 per share | ₹100.00 per share |
| Issue Price (Upper) | ₹603.00 per share | ₹102.00 per share |
| Issue Price (Final) | ₹603.00 per share | ₹102.00 per share |
| Discount (Retail) | ₹0.00 per share | |
| Discount (Employee) | ₹60.00 per share | |
| Market Lot Size | 24 shares | 10000 shares |
| Fresh Issue Size | 0 shares | 46,52,09,336 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹4,745.14 Cr |
| OFS Issue Size | 2,88,75,000 shares | 2,82,10,664 shares |
| OFS Issue Size (Amount) | up to ₹1,740.49 Cr | up to ₹287.75 Cr |
| Issue Size Total | 2,88,75,000 shares | 49,34,20,000 shares |
| Issue Size Total (Amount) | up to ₹1,740.49 Cr | up to ₹5,032.88 Cr |
Eris Lifesciences IPO opens on Jun 16, 2017, while IRB InvIT Fund InvIT opens on May 03, 2017. The closing date of Eris Lifesciences IPO and IRB InvIT Fund InvIT is Jun 20, 2017, and May 05, 2017, respectively.
| Eris Lifesciences IPO | IRB InvIT Fund InvIT | |
|---|---|---|
| Anchor Bid Date | Jun 15, 2017 | |
| Issue Open | Jun 16, 2017 | May 03, 2017 |
| Issue Close | Jun 20, 2017 | May 05, 2017 |
| Basis Of Allotment (Tentative) | Jun 23, 2017 | |
| Initiation of Refunds (Tentative) | Jun 27, 2017 | |
| Credit of Share (Tentative) | Jun 28, 2017 | |
| Listing date (Tentative) | Jun 29, 2017 | May 18, 2017 |
| Anchor Lockin End date 1 | Jul 23, 2017 | |
| Anchor Lockin End date 2 | Sep 21, 2017 |
Eris Lifesciences IPO P/E ratio is , as compared to IRB InvIT Fund InvIT P/E ratio of .
| Eris Lifesciences IPO | IRB InvIT Fund InvIT | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | ||||||
| Promoter Shareholding (Post-Issue) | ||||||
| P/E Ratio | ||||||
| Market Cap | ₹8291.25 Cr. | ₹5921.10 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW |
In the Eris Lifesciences IPO Retail Individual Investors (RII) are offered 28,72,500 shares while in IRB InvIT Fund InvIT retail investors are offered 28,72,500 shares. Qualified Institutional Buyers (QIB) are offered 86,17,500 shares in Eris Lifesciences IPO and 16,47,20,000 shares in IRB InvIT Fund InvIT.
| Eris Lifesciences IPO | IRB InvIT Fund InvIT | |
|---|---|---|
| Anchor Investor Reservation | 1,29,26,250 shares | 20,53,40,000 shares |
| Market Maker Reservation | 0 shares | |
| QIB | 86,17,500 shares | 16,47,20,000 shares |
| NII | 43,08,750 shares | 12,33,60,000 shares |
| RII | 28,72,500 shares | 0 shares |
| Employee | 1,50,000 shares | 0 shares |
| Others | ||
| Total | 2,88,75,000 shares | 49,34,20,000 shares |
Eris Lifesciences IPO subscribed 3.29x in total, whereas IRB InvIT Fund InvIT subscribed 8.57x.
| Eris Lifesciences IPO | IRB InvIT Fund InvIT | |
|---|---|---|
| QIB (times) | 4.68x | 10.81x |
| NII (times) | 0.45x | |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 3.51x | |
| Employee (times) | 0.86x | |
| Other (times) | 5.89x | |
| Total (times) | 3.29x | 8.57x |
